Are Surgeons Collecting Enough Tumor Tissue in Laparoscopic Biopsies for HRD Testing?-Are Surgeons Collecting Enough Tumor Tissue in Laparoscopic Biopsies for HRD Testing?

Are Surgeons Collecting Enough Tumor Tissue in Laparoscopic Biopsies for HRD Testing?

Video Transcription

Video Summary

The video content is a roundtable discussion on the topic of gaps in care related to collecting sufficient biopsies for homologous recombination deficiency (HRD) testing in ovarian cancer. The panel includes Dr. Tom Herzog as the moderator, along with Dr. Sharon Lewin, Dr. Gulisa Tereshavili, and Dr. Shannon Weston as the panelists. The discussion focuses on the importance of HRD testing in ovarian cancer, challenges in tumor testing, and ways to improve sample quantity and quality. Dr. Tereshavili highlights the challenges in tumor testing, such as the need for sufficient tumor cellularity, the influence of chemotherapy on tissue quality, and the importance of selecting the optimal samples for HRD testing. The panelists also discuss the clinical implications of HRD testing, including its impact on treatment decisions and patient outcomes. Additionally, the panel addresses questions from the audience, providing insights on reconciling contradictory results in HRD testing, the testing of tissue in recurrence cases, and the timeline and best methods for preparing and testing samples. The discussion emphasizes the importance of early and accurate HRD testing in guiding treatment decisions for ovarian cancer patients.

Keywords

gaps in care

biopsies

homologous recombination deficiency

HRD testing

ovarian cancer

roundtable discussion

panel

tumor testing

sample quantity

sample quality